PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
about
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsResistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerThe effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responseThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsExpression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.New advances in genitourinary cancer: evidence gathered in 2014.Immunotherapy of Prostate Cancer: Facts and Hopes.Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinomaCastration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.Multifaceted and personalized therapy of advanced prostate cancer.Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancerAntibody therapeutics for treating prostate cancer: where are we now and what comes next?Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.The inflammatory microenvironment and microbiome in prostate cancer development.Prostate cancer health disparities: An immuno-biological perspective.Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.PARP inhibitors for homologous recombination-deficient prostate cancer.ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.Perspectives on the clinical development of immunotherapy in prostate cancer.Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancerDendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right TimeEnzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
P2860
Q26740601-0E7F1F3A-9B87-438B-B0C0-26F46894AF4FQ26750672-E28F1EE0-D831-4681-9B83-7F0ED8C6678FQ26751237-27ACE2F6-4E2D-4C74-A295-55115C755634Q26766066-A7E8D716-EEA6-4819-8EFE-280C5B06EABDQ26797478-F00539DC-0144-4CB8-B7CA-E2D5F61213E7Q33276164-A5777BDA-3121-4322-BB47-1F637A0FBA77Q33814908-201DE715-AC09-4BDD-8FE9-3A29FF62A4F8Q34464312-C06B65F3-7F4F-4E6C-8996-AB4B4D5817C5Q36288987-8913D133-E2B9-4DDA-96ED-2460CA7147CFQ36398998-A21A2267-619E-48F9-A211-726E4BE9662FQ36567984-598DA198-80FD-437C-B52B-4B1F75C56974Q37335554-9417B50F-26D3-4B2D-A42B-6B87A0CAE271Q37457995-3947F863-AC19-483C-BC41-963FC3A5440CQ38557894-8DA9C1F2-5D9B-4668-B547-1F96D3F1AFEFQ38664882-8E059D8D-AC7C-47F3-947D-C76C8AB17A19Q38719539-A5580C4E-DCF0-4C14-B80D-60C6BF2FA773Q38728375-1CB5838B-8D86-4E24-8F42-596F32A6DB5CQ38780436-647A8E39-AF9C-4A9C-8996-688AD12A0AD4Q38887592-3595764E-3B5A-4FDD-A039-C977B055EE36Q39000185-BE10983C-4AE7-4DC5-B583-63279091E0B1Q39093352-39222F2F-6C65-4DC8-9F9B-61586E132D85Q39438805-99C38D68-2C8F-46F8-A20A-05782A2BA9ABQ41625490-9CB8C59C-8927-43B9-9C59-215C5D29E4EFQ42324670-B322C21D-C44B-4043-A70F-71FB9D9DE1E7Q45058251-188ADCF6-F975-49DD-B682-B3C34BE59EA0Q45952214-C59FB077-03FB-4CAC-9E14-42BB9D92C14BQ46271291-5AFDABFC-1A9F-4304-A4F9-A675D787914EQ46537204-C4918471-710C-47B3-A0FF-603850A6720BQ47109527-D063D483-6FE3-4A40-BE24-A0E1DCDA28ABQ50080908-C7704DA6-61A0-4388-8DB9-F97B0B694ED7Q52623144-83914474-5E27-47C6-AB91-9231F5167027Q52641296-FBA78445-9750-488D-AB9D-0C244F724863Q52657103-D1056B7A-19B5-410E-82A5-D89630D05160Q55029444-E2CD8EDA-DAA7-40AB-953F-9BBEFB6920ECQ56892705-5E0F804C-59FB-4A0F-89BF-799CCFBF6A49Q57486475-F08983AD-5058-4D56-99C1-DF87F450945DQ58698705-84A1C2B6-6EFF-489D-8E3D-71250F06A308
P2860
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
@en
type
label
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
@en
prefLabel
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
@en
P2093
P2860
P4510
P356
P1433
P1476
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
@en
P2093
Alexander Sio
Amina Zoubeidi
Arkhjamil Angeles
Arun A Azad
Jennifer L Bishop
P2860
P304
P356
10.18632/ONCOTARGET.2703
P407
P577
2015-01-01T00:00:00Z